<DOC>
	<DOCNO>NCT01286103</DOCNO>
	<brief_summary>The purpose study evaluate effect canagliflozin glucose level blood urine take 2 dose level once-daily twice-daily dose regimen healthy adult volunteer</brief_summary>
	<brief_title>A Pharmacokinetic Pharmacodynamic Study Once-Daily Twice-Daily Dosing With Canagliflozin Healthy Adult Volunteers</brief_title>
	<detailed_description>This open-label ( volunteer know name treatment assign ) , single-center study canagliflozin ( JNJ-28431754 ) healthy adult volunteer . Canagliflozin ( Sodium-Glucose Cotransporter 2 inhibitor ) currently development low blood sugar level patient type 2 diabetes mellitus ( T2DM ) . Patients Cohort 1 randomize receive Treatment A ( one 300-mg tablet orally , mouth [ PO ] daily 5 day ) follow 10 day later Treatment B ( one 50-mg one 100-mg tablet PO twice daily 5 day ) Treatment B follow Treatment A . Patients Cohort 2 randomize receive Treatment C ( one 100-mg tablet PO daily 5 day ) follow 10 day later Treatment D ( one 50-mg tablet PO twice daily 5 day ) Treatment D follow Treatment C .</detailed_description>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Healthy volunteer body mass index ( BMI , measure person 's weight relation height ) 18 30 kg/m2 , inclusive , body weight less 50 kg History current clinically significant medical illness determine Investigator History clinically significant allergy , especially know hypersensitivity intolerance lactose Known allergy canagliflozin excipients formulation canagliflozin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>